Before its COVID-19 era hype, ivermectin was already a wonder drug for parasitic infections. Its renewed interest underscores the need for effective COVID-19 treatments and communication on proper research study design and analysis.
Scientists continue to ring alarm bells about the risks associated with the continued misuse of antimicrobials and advocate for innovative treatments, improved surveillance, and greater public health education.
A GLP-grade non-replicative Leishmaniamajor parasite protects hamsters from lethal leishmaniasis infection, setting the stage for human clinical trials and the first potential vaccine for leishmaniasis.
Respiratory viruses are the most common cause of asthma attacks, but COVID-19 does not send asthma patients to the hospital more often than others. Some researchers suspect that having asthma may actually protect patients from severe COVID-19.